Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PHAR
stocks logo

PHAR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 39.50 USD with a low forecast of 37.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 39.50 USD with a low forecast of 37.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 17.350
sliders
Low
37.00
Averages
39.50
High
42.00
Current: 17.350
sliders
Low
37.00
Averages
39.50
High
42.00
Oppenheimer
Oppenheimer
Outperform
maintain
$41 -> $42
2025-11-07
Reason
Oppenheimer
Oppenheimer
Price Target
$41 -> $42
2025-11-07
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Pharming to $42 from $41 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3 results with $97M in sales, meaningfully above its estimates and generally in line with consensus of $90M/$98M, respectively.
Oppenheimer
Jeff Jones
Outperform
maintain
$40 -> $41
2025-08-01
Reason
Oppenheimer
Jeff Jones
Price Target
$40 -> $41
2025-08-01
maintain
Outperform
Reason
Oppenheimer analyst Jeff Jones raised the firm's price target on Pharming to $41 from $40 and keeps an Outperform rating on the shares after the company announced Q2 results. Moving into the second half of 2025, Oppenheimer anticipates competitive pressure on Ruconest from Ekterly, potentially up to a 20% hit by year-end 2026 as patients try the oral option, its estimates counterbalanced by reduced expenses.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$37
2025-03-21
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$37
2025-03-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$37
2025-03-20
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$37
2025-03-20
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$37
2025-03-14
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$37
2025-03-14
Reiterates
Strong Buy
Reason
Oppenheimer
Michael Carrier
Buy
Maintains
$30 → $39
2025-03-14
Reason
Oppenheimer
Michael Carrier
Price Target
$30 → $39
2025-03-14
Maintains
Buy
Reason
Oppenheimer raised the firm's price target on Pharming to $39 from $30 and keeps an Outperform rating on the shares following quarterly results. The firm notes 2024 revenue of $297M came in above its/consensus' estimates of $289/262M, as well as prior top-end guidance of $295M. Addition of KL1333 to the portfolio contributes the majority of the $9 added to the firm's new price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pharming Group NV (PHAR.O) is 223.87, compared to its 5-year average forward P/E of -59.73. For a more detailed relative valuation and DCF analysis to assess Pharming Group NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-59.73
Current PE
223.87
Overvalued PE
204.68
Undervalued PE
-324.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
142.25
Current EV/EBITDA
48.45
Overvalued EV/EBITDA
401.61
Undervalued EV/EBITDA
-117.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
2.78
Current PS
2.91
Overvalued PS
3.44
Undervalued PS
2.13
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

PHAR News & Events

Events Timeline

(ET)
2025-12-03
07:00:00
Pharvaris Announces RAPIDe-3 Pivotal Data Confirming Deucrictibant's Treatment Potential
select
2025-04-23 (ET)
2025-04-23
10:50:12
Pharming announces positive recommendation from NICE for Joenja
select
2025-01-21 (ET)
2025-01-21
16:22:10
Pharming to nominate Fabrice Chouraqui as new CEO, succeeding Sijmen de Vries
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-01Globenewswire
Pharma Equity Group Issues DKK 8.8M Convertible Loans to Strengthen Capital Structure
  • Financing Scale: Pharma Equity Group has decided to issue convertible loans totaling up to DKK 8.8 million, aimed at strengthening the company's capital structure and supporting future growth.
  • Repayment Arrangement: This issuance will repay existing convertible loans and a credit facility, ensuring financial stability and reducing debt burden for the company.
  • Conversion Terms: The new loans have a conversion price of DKK 0.12 per share, with the conversion right exercisable within 30 days after the 24th month post-loan conclusion, enhancing potential returns for shareholders.
  • Strategic Goals: Pharma Equity Group focuses on its subsidiary Reponex Pharmaceuticals' drug candidates, planning to accelerate the development of its medical projects through this financing, ensuring long-term growth.
[object Object]
Preview
7.0
11-27Globenewswire
Pharma Equity Group Corrects 2024 Annual Report and H1 2025 Interim Report
  • Accounting Correction Impact: Following an order from the Danish Business Authority, Pharma Equity has reduced the carrying amount of its receivable from Portinho from DKK 58 million to DKK 41.812 million in the 2024 Annual Report, resulting in an increased loss of DKK 16.188 million for 2024, highlighting the importance of financial transparency for the company.
  • Interim Report Adjustment: For H1 2025, the fair value of the Portinho receivable has been reassessed to DKK 33.697 million, down from DKK 58 million, reflecting significant challenges in the company's accounts receivable management.
  • Financial Impact Analysis: This correction reduces total assets and equity for 2024 and H1 2025 to DKK 49.418 million and DKK 15.076 million respectively, underscoring the risks associated with the company's receivables management.
  • Liquidity Unaffected: Management emphasizes that this correction is purely accounting in nature and does not affect the company's liquidity or cash flow, demonstrating the company's resilience and ongoing efforts to maximize recovery through negotiations.
[object Object]
Preview
9.5
11-13Benzinga
Pharming Group Reports Positive Q3 Results, Alongside On Holding, BigBear.ai Holdings, and Other Major Stocks Rising on Wednesday

  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones index increasing by over 300 points on Wednesday.

  • Pharming Group's Financial Success: Pharming Group N.V. saw a significant share price increase of 5.9% to $17.17 after reporting better-than-expected Q3 results and raising its FY25 sales guidance.

  • Notable Stock Gains: On Holding AG's shares surged 23% to $43.27 following positive Q3 results, while BigBear.ai Holdings gained 20.1% to $7.28 after announcing an acquisition and strong quarterly results.

  • Other Companies with Strong Performance: McGraw Hill, Perion Network, ChipMOS Technologies, Datavault AI, and CorMedix also reported substantial gains in their stock prices after positive financial results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pharming Group NV (PHAR) stock price today?

The current price of PHAR is 17.35 USD — it has increased 9.74 % in the last trading day.

arrow icon

What is Pharming Group NV (PHAR)'s business?

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

arrow icon

What is the price predicton of PHAR Stock?

Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 39.50 USD with a low forecast of 37.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pharming Group NV (PHAR)'s revenue for the last quarter?

Pharming Group NV revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Pharming Group NV (PHAR)'s earnings per share (EPS) for the last quarter?

Pharming Group NV. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Pharming Group NV (PHAR)'s fundamentals?

The market is revising Upward the revenue expectations for Pharming Group N.V. (PHAR) for FY2025, with the revenue forecasts being adjusted by 1.95% over the past three months. During the same period, the stock price has changed by 13.70%.
arrow icon

How many employees does Pharming Group NV (PHAR). have?

Pharming Group NV (PHAR) has 382 emplpoyees as of December 05 2025.

arrow icon

What is Pharming Group NV (PHAR) market cap?

Today PHAR has the market capitalization of 1.19B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free